Characterising variations in the salinity of deep groundwater systems: A case study from Great Britain (GB)

Study region The study region is Great Britain (GB), a small non-continental island landmass in North West Europe Study focus Data for Total Dissolved Solids (TDS) from groundwater samples can be used to characterise regional-scale variations in the quality of deep groundwater systems. Combined with information about typical well-depths, TDS data can be used to identify the presence of currently undeveloped fresh or brackish groundwater at depth that may require protection. This study considers the distribution of TDS with depth relative to sea level in the main GB aquifers and selected other key hydrogeological units, and demonstrates how useful insights can be obtained from data-led analyses of depth variations in groundwater chemistry if the regional context of hydrogeological systems is taken into account. New hydrogeological insights In GB, TDS varies over about five orders of magnitude, up to about 330,000 mg/L, with a general increase in mineralisation with depth. Overall, there is a transition from fresh 10,000 mg/L groundwater at about 700 m. Given that the 95 %tile depth of water wells is about 200 m, it is evident that there is currently undeveloped fresh groundwater at depth across large parts of the study area that may require protection, although it is inferred that TDS is not the only factor limiting exploitation and use of these deeper resources. As in this study, previous data-led analyses of fresh groundwater at depth have typically analysed TDS as depth below surface. However, if TDS data is analysed relative to sea level and in the context of regional hydrogeological information or models, additional insights can be gained on the distribution and controls on fresh groundwater at depth. Projecting TDS data into a 3D hydrogeological model of the study area shows that fresh groundwater at depth exhibits spatial coherence and is generally associated with relatively dee

3D Groundwater Vulnerability

This report is the product of a joint British Geological Survey (BGS) – Environment Agency (EA) study to assess the vulnerability of groundwater in relation to deep sub-surface hydrocarbon activity (3D Groundwater Vulnerability) in England. Since the late 1980s, groundwater protection in England has benefited from a series of national groundwater vulnerability maps. These are now routinely used to inform decisions around allowing and/or managing activities on, or just below, the land surface that are potentially polluting. The recent increased interest in onshore exploration and exploitation of the deeper subsurface and concerns about the risk to groundwater has highlighted the fact that the existing groundwater vulnerability assessment methodology focuses solely on risks from hazards that are above the groundwater that requires protection. Plans to exploit the deep sub-surface, in particular for shale gas using hydraulic fracturing, have attracted considerable public interest and concerns over the potential for these activities to cause pollution of groundwater. It is therefore essential that in considering any proposals for use of the deep sub-surface, tools and methods for assessing groundwater vulnerability and risk are fit for purpose. Hence, the aim of this project was to develop a new vulnerability method that could address the potential risks to groundwater from activities below, or at similar depths to, groundwater systems (aquifers) that are currently used or have the potential to be used in the future. These systems are those requiring protection under current EU and UK legislation. To this end we present a methodology along with five different hydrocarbon activity case study examples from across England. The report describes how information can be compiled, interpreted and presented in order to assess the vulnerability of groundwater and an indication of the risks associated with a hydrocarbon development activity at a site. The outputs are designed for use primarily by those needing to understand better the hydrogeological context of subsurface developments, the vulnerability of groundwater and the potential risks. It is also hoped that the hydrogeological data and methodology will aid decision making and provide impartial information to inform public debate. The report is not designed to set out in a formal way how information and modelling should be used to reach regulatory decisions. A wider set of site-specific information will be required for this and this is outside the scope of the research presented here

Phase stability of the AlxCrFeCoNi alloy system

The addition of Al to the A1 CrFeCoNi alloy has been shown to promote the formation of intermetallic phases, offering possibilities for the development of alloys with advantageous mechanical properties. However, despite numerous experimental investigations, there remain significant uncertainties as to the phase equilibria in this system particularly at temperatures below 1000°C. The present study makes a systematic assessment of the literature data pertaining to the equilibrium phases in alloys of the AlxCrFeCoNi system. Two alloys, with atomic ratios, x = 0.5 and 1.0, are then selected for further experimental investigation, following homogenisation (1200°C/72 h) and subsequent long-duration (1000 h) heat-treatments at 1000, 850 and 700°C. The Al0.5 alloy was found to be dual-phase A1 + B2 in the homogenised condition and following exposure at 1000°C but D8b phase precipitates developed following heat-treatment at the lower temperatures. In the Al1.0 alloy, B2, A2 and A1 phases were identified in the homogenised condition and at 1000°C. At 850 and 750°C, the A2 phase was replaced by the D8b phase. These experimental observations were used alongside literature data to assess the veracity of CALPHAD predictions made using the TCHEA4 thermodynamic database

A method for screening groundwater vulnerability from subsurface hydrocarbon extraction practices

This paper describes a new screening method for assessing groundwater vulnerability to pollution from hydrocarbon exploitation in the subsurface. The method can be used for various hydrocarbon energy sources, including conventional oil and gas, shale gas and oil, coal bed methane and underground coal gasification. Intrinsic vulnerability of potential receptors is assessed at any particular location by identifying possible geological pathways for contaminant transport. This is followed by an assessment of specific vulnerability which takes into account the nature of the subsurface hydrocarbon activity and driving heads. A confidence rating is attached to each parameter in the assessment to provide an indication of the confidence in the screening. Risk categories and associated confidence ratings are designed to aid in environmental decision making, regulation and management, highlighting where additional information is required. The method is demonstrated for conventional gas and proposed shale gas operations in northern England but can be adapted for use in any geological or hydrogeological setting and for other subsurface activities

Assessing the reach and engagement with the “How To Save A Life” mass media campaign on drug-related death prevention in Scotland

‘How To Save A Life’ (HTSAL) was a mass media campaign on drug-related death prevention which ran in Scotland from August 2021 to January 2022. It aimed to increase awareness of how to respond to an opioid overdose, and the uptake of take-home naloxone (THN). The objective of this study was to determine the reach and engagement with the campaign. Methods included a descriptive analysis of data from media sources, the campaign website, and an online naloxone training course. A quantitative content analysis was conducted on media articles. The campaign generated 57,402,850 non-unique impressions (the total number of times the campaign was seen or heard), and unique reach (the number of people who were exposed to the campaign) figures of 2,621,450. Engagement with the campaign was positive, and 96% of print/digital media articles had a positive view of the campaign. There were 40,714 visits to the campaign website, leading to 8,107 clicks to the free naloxone training course, and 3,141 clicks to order a free naloxone kit. This study showed that mass media campaigns on drug policy topics can achieve high levels of reach and engagement. There was a clear progression from viewing campaign materials, to visiting the campaign website, to completing naloxone training. Our research suggests that mass media campaigns can be used to disseminate harm reduction messages to the general public

Extreme Ultra-Violet Spectroscopy of the Lower Solar Atmosphere During Solar Flares

The extreme ultraviolet portion of the solar spectrum contains a wealth of diagnostic tools for probing the lower solar atmosphere in response to an injection of energy, particularly during the impulsive phase of solar flares. These include temperature and density sensitive line ratios, Doppler shifted emission lines and nonthermal broadening, abundance measurements, differential emission measure profiles, and continuum temperatures and energetics, among others. In this paper I shall review some of the advances made in recent years using these techniques, focusing primarily on studies that have utilized data from Hinode/EIS and SDO/EVE, while also providing some historical background and a summary of future spectroscopic instrumentation.Comment: 34 pages, 8 figures. Submitted to Solar Physics as part of the Topical Issue on Solar and Stellar Flare

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

Interindividual clinical variability in the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is vast. We report that at least 101 of 987 patients with life-threatening coronavirus disease 2019 (COVID-19) pneumonia had neutralizing immunoglobulin G (IgG) autoantibodies (auto-Abs) against interferon-w (IFN-w) (13 patients), against the 13 types of IFN-a (36), or against both (52) at the onset of critical disease; a few also had auto-Abs against the other three type I IFNs. The auto-Abs neutralize the ability of the corresponding type I IFNs to block SARS-CoV-2 infection in vitro. These auto-Abs were not found in 663 individuals with asymptomatic or mild SARS-CoV-2 infection and were present in only 4 of 1227 healthy individuals. Patients with auto-Abs were aged 25 to 87 years and 95 of the 101 were men. A B cell autoimmune phenocopy of inborn errors of type I IFN immunity accounts for life-threatening COVID-19 pneumonia in at least 2.6% of women and 12.5% of men

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p<0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p<0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570